Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Wednesday, December 19, 2018 · 471,523,799 Articles · 3+ Million Readers

Systemic Mastocytosis Therapeutic and Disease Pipeline Review H2

Systemic Mastocytosis Pharmaceutical and Healthcare Pipeline Review H2

PUNE, INDIA, November 13, 2017 / -- Summary
Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 1 respectively.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Systemic Mastocytosis - Overview 6
Systemic Mastocytosis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Systemic Mastocytosis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Systemic Mastocytosis - Companies Involved in Therapeutics Development 19
AB Science SA 19
AbbVie Inc 19
Arog Pharmaceuticals Inc 20
Blueprint Medicines Corp 20
Bristol-Myers Squibb Co 21
Deciphera Pharmaceuticals LLC 21
Patara Pharma Inc 21


Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release